Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LASN01 in Healthy Subjects and Patients With Pulmonary Fibrosis or Thyroid Eye Disease
NCT05331300Phase 2Completed
- Sponsor
- Lassen Therapeutics
- Start
- Jun 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of LASN01 in idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), thyroid eye disease (TED), sponsored by Lassen Therapeutics. Started Jun 2022; status: completed.
02
Drugs
LASN01
03
Conditions
idiopathic pulmonary fibrosis (IPF)progressive fibrosing interstitial lung disease (PF-ILD)thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT05331300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05331300.